Literature DB >> 12496742

More efficient clinical trials through use of scientific model-based statistical tests.

E Niclas Jonsson1, Lewis B Sheiner.   

Abstract

Mesh：

Year:  2002        PMID： 12496742     DOI： 10.1067/mcp.2002.129307

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  21 in total

1.  A joint model for nonlinear longitudinal data with informative dropout.

Authors:  Chuanpu Hu; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

2.  Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9.

Authors:  Kerenaftali Klein; Ivelina Gueorguieva; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-21       Impact factor: 2.745

3.  Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

Authors:  Camille Vong; Martin Bergstrand; Joakim Nyberg; Mats O Karlsson
Journal:  AAPS J       Date:  2012-02-17       Impact factor: 4.009

Review 4.  Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Authors:  Goonaseelan Colin Pillai; France Mentré; Jean-Louis Steimer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

5.  Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies.

Authors:  Jakob Ribbing; Andrew C Hooker; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-11-08       Impact factor: 2.745

6.  Disease progression, drug action and Parkinson's disease: why time cannot be ignored.

Authors:  Nick Holford; John G Nutt
Journal:  Eur J Clin Pharmacol       Date:  2007-12-19       Impact factor: 2.953

7.  Randomized exposure-controlled trials; impact of randomization and analysis strategies.

Authors:  Kristin E Karlsson; Anders Grahnén; Mats O Karlsson; E Niclas Jonsson
Journal:  Br J Clin Pharmacol       Date:  2007-04-10       Impact factor: 4.335

8.  Optimizing disease progression study designs for drug effect discrimination.

Authors:  Sebastian Ueckert; Stefanie Hennig; Joakim Nyberg; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-27       Impact factor: 2.745

9.  A longitudinal model for non-monotonic clinical assessment scale data.

Authors:  Fredrik Jonsson; Scott Marshall; Michael Krams; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

10.  Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

Authors:  S F Marshall; R Burghaus; V Cosson; S Y A Cheung; M Chenel; O DellaPasqua; N Frey; B Hamrén; L Harnisch; F Ivanow; T Kerbusch; J Lippert; P A Milligan; S Rohou; A Staab; J L Steimer; C Tornøe; S A G Visser
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.